Immediate optimal endocrine adjuvant therapy versus standard chemotherapy followed by the same endocrine therapy in pre- or peri-menopausal patients with early hormone receptor-positive breast cancer - the Promise study.
Phase of Trial: Phase III
Latest Information Update: 08 May 2012
At a glance
- Drugs Anastrozole; Cyclophosphamide; Epirubicin; Fluorouracil; Goserelin
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms PROMISE
- 08 May 2012 New source identified and integrated (Netherlands Trial Register; NTR357).
- 04 Jan 2012 Actual end date (Dec 2011) added as reported by ISRCTN: Current Controlled Trials.
- 04 Jan 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.